Newsletter Tool

Today's Rundown

Amazon using its scale, consumer focus to reimagine primary care, Care Medical exec says
Moderna CEO Bancel set for a soft landing as his golden parachute swells to $926M
FDA slams Philips' 'inadequate' efforts to notify patients, suppliers of CPAP recall
Capricor culls COVID-19 vax work but eyes phase 3 for Duchenne therapy
Immunome's COVID-19 antibody cocktail back on track for phase 1 after FDA lifts hold
Ramping up domestic production won't solve US medical supply chain challenges: report
Pfizer's softly, softly, COVID marketing approach continues with new drug ad
Medtronic taps Apple partner Rockley Photonics to build biomarker-sensing wearables
Amid inflation spike, execs at J&J, Bayer, GSK and more talk higher costs—and what it means for profits
Texas, southern states had large spikes in ACA coverage for 2022 thanks to boosted subsidies
Histogen seeks to tear up COVID-19 R&D pact and go solo, accuses Amerimmune of failing to push on into phase 2
RISE 2022: Don't expect COVID-19 to be done as wave dissipates, former CDC official Nancy Messonnier says
RefleXion collects $80M after scoring breakthrough tag for its PET-guided radiotherapy
Concert tunes pipeline by selling off CNS assets to startup Terran Biosciences
Stevanato's growth spree rolls on with China plant purchase, plans for 270 jobs

Featured Story

Amazon using its scale, consumer focus to reimagine primary care, Care Medical exec says

By Heather Landi

MIAMI—Sunita Mishra, M.D., spent more than 15 years in medical practice as an internist and primary care doctor and then moved over to Amazon Care to serve as the medical director at Care Medical. Here's why Mishra is bullish on Amazon's ability to use its scale and consumer-centric focus to build a "world-class patient experience."

Moderna CEO Bancel set for a soft landing as his golden parachute swells to $926M

By Kevin Dunleavy

Moderna CEO Stéphane Bancel's golden parachute now clocks in at $926 million, the company revealed in its proxy report earlier this week. The news comes after a transformational year for the company as its revenues went from $803 million in 2020 to $18.5 billion last year amid its worldwide COVID-19 vaccine launch.

FDA slams Philips' 'inadequate' efforts to notify patients, suppliers of CPAP recall

By Andrea Park

Nine months into Philips’ wide-ranging Class I recall of many of its CPAP and BiPAP machines and other respiratory devices, the FDA isn’t entirely pleased with how the company has handled the recall.

Capricor culls COVID-19 vax work but eyes phase 3 for Duchenne therapy

By Kyle LaHucik

Capricor Therapeutics will get enrollment underway in a phase 3 trial for its Duchenne muscular dystrophy cell therapy next quarter, while development of a COVID-19 vaccine is coming to a halt.

Immunome's COVID-19 antibody cocktail back on track for phase 1 after FDA lifts hold

By Max Bayer

Immunome’s antibody cocktail COVID-19 treatment is free from an FDA hold, two months after the pause was first placed.

Ramping up domestic production won't solve US medical supply chain challenges: report

By Anastassia Gliadkovskaya

While it’s no secret how heavily the U.S. relies on other countries for medical imports, the report challenged the widely suggested solution of increasing domestic production as a way of increasing supply chain resilience.

Pfizer's softly, softly, COVID marketing approach continues with new drug ad

By Ben Adams

Pfizer’s COVID vaccine ads have been light on branding and strong on “human spirit,” and that subtle marketing approach continues—though with a small difference—in its first commercial for COVID-fighting pills.

Medtronic taps Apple partner Rockley Photonics to build biomarker-sensing wearables

By Andrea Park

The partnership will combine Rockley’s recently launched biosensing technology and Medtronic’s decades of experience developing patient-facing tools and services.

Amid inflation spike, execs at J&J, Bayer, GSK and more talk higher costs—and what it means for profits

By Eric Sagonowsky

While inflation is top of consumers' minds right now, pharma companies are also feeling the pain of higher prices when it comes to profit margins. During recent discussions with analysts, execs with Johnson & Johnson, Bayer, GlaxoSmithKline and more talked about the higher prices facing their businesses.

Texas, southern states had large spikes in ACA coverage for 2022 thanks to boosted subsidies

By Robert King

Texas and several other southern states saw increases of 30% or more in sign-ups for 2022 Affordable Care Act coverage, with sign-ups boosted by enhanced subsidies that expire after this year.

Histogen seeks to tear up COVID-19 R&D pact and go solo, accuses Amerimmune of failing to push on into phase 2

By Nick Paul Taylor

The collaboration between Histogen and Amerimmune has soured. Believing Amerimmune has failed to meet its R&D responsibilities, Histogen is seeking to terminate the collaboration agreement and retake control of the COVID-19 development program.

RISE 2022: Don't expect COVID-19 to be done as wave dissipates, former CDC official Nancy Messonnier says

By Robert King

NASHVILLE, Tenn.—Former CDC official Nancy Messonnier told the crowd at RISE 2022 that the worst of the omicron COVID-19 surge is over but the pandemic is not done yet.

RefleXion collects $80M after scoring breakthrough tag for its PET-guided radiotherapy

By Conor Hale

Radiotherapy specialist RefleXion Medical has raised $80 million to help broaden its cancer offerings after recently exploring the company’s potential in treating prostate cancer and other tumors.

Concert tunes pipeline by selling off CNS assets to startup Terran Biosciences